close

Enter

Log in using OpenID

Acute Lymphoblastic Leukemia Therapeutics Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

embed
Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The condition is characterized by overproduction of immature white blood cells, also known as lymphoblast.
Acute Lymphoblastic Leukemia Therapeutics
Market - Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2018-2026
Acute lymphoblastic leukemia (ALL) is a type of cancer affecting the bone marrow and blood. The
condition is characterized by overproduction of immature white blood cells, also known as
lymphoblast. The immature or abnormal cells are unable to function properly and build up around the
healthy cells. Patients diagnosed with ALL are highly susceptible to recurrent infections, anemia,
bleeding and bruising easily as the bone marrow is unable to form adequate numbers of red blood
cells, white blood cells, and platelets. The cancer is characterized with high progression rate, and can
be fatal if not treated within few months. The cancerous cells have the potential to spread to other
organs of the body including lymph nodes, liver, spleen, and the central nervous system. The
common symptoms of the condition include renal failure, pneumonia, respiratory distress, and bone
pain. Acute lymphocytic leukemia is the most common type of cancer in children, where timely
treatment and diagnosis results in efficient cure of the condition.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1606
Regional Dynamics
Regional segmentation of the global acute lymphoblastic leukemia therapeutics market by
Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacifc, Middle
East, and Africa. North America is expected to hold a dominant position in the global acute
lymphoblastic leukemia therapeutics market over the forecast period, owing to rising prevalence
of the disease and rising number of clinical trials undertaken by organizations in the region to
address the unmet medical needs of patients. According to the American Cancer Society, 2016,
an estimated 5,970 new ALL diagnoses and 1,440 deaths from ALL were registered in 2017. Also,
according to the St. Jude Children’s Research Hospital, about 3,000 people aged below 20 years
are found to have acute lymphoblastic leukemia each year in the U.S.
Moreover, the St. Jude Children’s Research Hospital, U.S. is focusing on improving outcomes for
children with leukemia by undertaking clinical trials to develop novel therapeutics for the
condition. For instance, in 2012, the St. Jude Children’s Research Hospital initiated trials for
ALLR18 for pediatric relapsed or refractory precursor B-cell acute lymphoblastic leukemia.
Moreover, in 2015, Juno Therapeutics, Inc. developed JCAR015 (CD19-targeted CAR T cells),
which is currently in the Phase 2 clinical trial, indicated for treating adults with relapsed or
refractory B-cell acute lymphoblastic leukemia (B-ALL).
Report includes chapters which deeply display the following deliverable about industry :
•Acute Lymphoblastic Leukemia Therapeutics Market Research Objective and Assumption
•Acute Lymphoblastic Leukemia Therapeutics Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
•Acute Lymphoblastic Leukemia Therapeutics Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• GlobalAcute Lymphoblastic Leukemia Therapeutics Market, By Regions
•Acute Lymphoblastic Leukemia Therapeutics Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
•Acute Lymphoblastic Leukemia Therapeutics Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
•Acute Lymphoblastic Leukemia Therapeutics Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
•Acute Lymphoblastic Leukemia Therapeutics Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key players operating in the global acute lymphoblastic leukemia therapeutics market
include Novartis Pharmaceuticals, Pfzer Inc., Genzyme Corporation, GlaxoSmithKline
Plc., ERYTECH Pharma, Talon Therapeutic, Inc., Sigma-Tau Pharmaceuticals, Inc.,
Spectrum Pharmaceuticals, Inc. F. Hofmann-La Roche Ltd., Biogen Idec, Inc., BristolMyers Squibb, and Celgene Corporation.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1606
Market Taxonomy
On the basis of drug type, global acute lymphoblastic leukemia therapeutics market is
segmented into:
• Chemotherapy Drugs
• Nelarabine (Arranon)
• Blinatumomab (Blincyto)
• Clofarabine (Clolar)
• Erwinia (Erwinase)
• Pegaspargase (Oncaspar)
• Vincristine (Marqibo)
• Others
• Immunotherapy Drugs
• Tisagenlecleucel (Kymriah)
• Targeted Therapy Drugs
• Imatinib (Gleevec)
• Dasatinib (Sprycel)
• Nilotinib (Tasigna)
• Others
• Others
On the basis of indication, global acute lymphoblastic leukemia therapeutics market is
segmented into:
• Precursor B Cell ALL
• Mature B Cell ALL
• Precursor T Cell ALL
On the basis of distribution channel, the global acute lymphoblastic leukemia therapeutics
market is segmented into:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
On the basis of region, the global acute lymphoblastic leukemia therapeutics market is
segmented into:
•
•
•
•
•
•
North America
Latin America
Europe
Asia Pacifc
Middle East
Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
1/--pages
Report inappropriate content